AtlasXomics September Newsletter
Epigenomic Plasticity, Disease Programs & New Spatial Methods | September 2025
This month’s picks spotlight how epigenomic plasticity shapes therapy response, how regulatory programs drive disease, and how new spatial methods open fresh windows into tissue biology. From enhancer addiction in LUSC to near single-cell spatial DNA-methylome maps, we’re seeing the field converge on multi-omic context at cellular resolution.
Spatial joint profiling of DNA methylome and transcriptome in tissues
Introduces near single-cell co-profiling of DNA methylation and the transcriptome in the same tissue section, expanding spatial multi-omics.
Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma
LUSC cells depend on tumor-specific enhancer programs; multi-omics pinpoints a targetable PTPRZ1–MDK axis driving growth.
Multi-omics single-cell analysis reveals key regulators of HIV-1 persistence
Identifies Th17 cells as the primary HIV reservoir and highlights KLF2 activity and interferon-linked dysfunction in infected CD4+ T cells.
Single-nucleus chromatin accessibility profiling identifies cell-type-specific alterations in MDD
Pinpoints deep-layer excitatory neurons with altered accessibility and risk-variant enrichment; microglia show reduced accessibility at immune-homeostasis loci.
Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance
Drug resistance is encoded in heritable “plasticity” programs that let tumor cells switch phenotypes under treatment pressure—arguing for adaptive epigenomic biomarkers.